The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation

Affiliation auteurs!!!! Error affiliation !!!!
TitreThe impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation
Type de publicationJournal Article
Year of Publication2020
AuteursNagler A, Dholaria B, Labopin M, Socie G, Huynh A, Itaelae-Remes M, Deconinck E, Yakoub-Agha I, Cahn J-Y, Bourhis J-H, Labussiere-Wallet H, Chantepie S, Esteve J, Savani B, Mohty M
JournalLEUKEMIA
Volume34
Pagination1144-1153
Date PublishedAPR
Type of ArticleArticle
ISSN0887-6924
Résumé

{Measurable residual disease (MRD) status pre-allogeneic hematopoietic cell transplantation (allo-HCT) has been shown to predict transplant outcomes. We investigated the effect of Anti-Thymocyte Globulin (ATG) on acute myelogenous leukemia (AML) relapse by pretransplant MRD status. AML patients undergoing allo-HCT in first complete remission from either a matched sibling or unrelated donor during the 2006-2017 period were selected. Outcomes of 1509 patients (MRD+
DOI10.1038/s41375-019-0631-5